^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Innovent Biologics Press Release
    Title:

    Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China

    Published date:
    10/09/2020
    Excerpt:
    Innovent Biologics, Inc....and Eli Lilly and Company...today jointly announce that HALPRYZA® (rituximab injection), a recombinant human/murine chimeric monoclonal antibody drug co-developed by Innovent and Lilly, has been officially approved by the National Medical Products Administration (NMPA) of China for patients with diffuse large b cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) in China.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    08/30/2022
    Excerpt:
    The following regimens are included as options for relapsed/refractory disease regardless of patient’s age or comorbidities...HDMP + rituximab or obinutuzumab (category 2B)
    Secondary therapy:
    methylprednisolone acetate
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma…Other recommended regimens…Rituximab ± Fludarabine, Bendamustine, High dose Methylprednisone, Clorambucil
    Secondary therapy:
    fludarabine oral; bendamustine; methylprednisolone oral; chlorambucil